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Introduction
The challenge to meet the nutritional goals of the extreme-
ly low birth weight (ELBW) infant while attempting to avoid 
serious complications and adverse outcomes such as necro-
tizing enterocolitis (NEC) can be overcome with human 
milk.1,2 Such a diet meets nutritional needs as well as pro-
vides health benefits to the recipient.
Mother’s own milk
It has been demonstrated that a diet comprised of mother’s 
own milk (MOM) is beneficial for ELBW infants because of 
its role in the protection from infection-related events, 
such as late onset sepsis (LOS), NEC, and urinary tract 
infection.3-7 It has been found that the human milk-fed 
ELBW infant is protected even after their NICU stay. There 
are fewer readmissions to the hospital for respiratory ill-
ness through almost 3 years in those ELBW infants who 
received predominantly human milk during their NICU stay.8
There is a 50% reduction in the rate of NEC and/or LOS 
and a shortened length of hospital stay among the ELBW 
infants receiving MOM at an average daily dose of more 
than 50 mL/kg compared to MOM + formula, or formula 
alone.3 That observation suggested that the dose of MOM 
(more than approximately 50mL/kg/day) was important to 
detect a beneficial health effect in ELBW infants.3
The concept of a “dose-dependent” protective effect of 
human milk has been reported elsewhere. ELBW infants 
receiving more than 50% MOM in the first 14 days after birth 
had an 83% reduction in the subsequent development of NEC 
compared to those receiving a diet of less than 50% MOM.9 A 
daily intake of more than 50mL/kg for 4 weeks also is asso-
ciated with a lower rate of neonatal sepsis.10 The dose-de-
pendent benefit should not be considered maximized at 50% 
intake. In a large retrospective analysis of 1272 infants, the 
likelihood of NEC or death after 14 days was decreased by a 
factor of 0.83 for each 10% increase in the proportion of 
total intake as human milk, suggesting the importance of 
dose and the predominance of a human milk diet.11 Even 
earlier initiation of MOM, >50% of total intake, is associated 
subsequently with a lower incidence of NEC, sepsis, and/or 
death during the first 60 days after birth.6 An even stronger 
prediction model was observed if the intake of MOM was 
more than 50% during days 6 to 10 after birth.6 These studies 
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suggest that in the ELBW population the important early pro-
tective effects of a human milk diet are long-lasting.
There are effects of human milk on the gastrointestinal 
tract of ELBW infants that account for the better accep-
tance of this milk when compared to formula. There are 
significantly fewer gastric residuals and less time feedings 
were withheld in infants receiving MOM versus formula.3 
Milestones, such as achievement of full enteral feeding and 
length of hospital stay, are significantly shortened with the 
feeding of MOM. These milestones are achieved in nearly 
twice as many days when the percentile of human milk 
intake was less than 20% as compared to more than 80%.12
Human milk feeding in ELBW infants also has been shown 
to protect against retinopathy of prematurity and, its most 
severe form, retinal detachment.13,14 These observations 
support a role of human milk as an antioxidant as well as 
containing factors that affect angiogenesis.
Pathogenesis of NEC
Clinical studies demonstrate that human milk protects the 
ELBW infant from NEC. To understand this relationship it is 
important to describe a general overview of the pathogen-
esis of NEC. The etiology of NEC is unknown, but it is prob-
ably caused by multiple factors in a presumably genetically 
susceptible host. Factors implicated in its pathogenesis 
include prematurity (immature intestinal function), milk 
feeding (substrate), microbial colonization, impaired muco-
sal defense, and to some degree, circulatory instability. 
These factors act together to cause mucosal injury, which 
appears to be the initial event.15,16
Bacterial colonization plays a pivotal role in the pathogen-
esis of NEC. Colonization of the normal GI tract occurs rap-
idly after delivery. The normal colonization is altered by the 
NICU environment. Immature intestinal motility predisposes 
to bacterial overgrowth which is unchecked due to the coex-
istence of an immature mucosal host defense. Increased gas-
trointestinal permeability potentiates bacterial transloca-
tion. Intestinal signaling becomes disrupted. Thus, these 
factors support and promote the invasion of pathogenic 
organisms into the circulation and set up an immune activa-
tion with an intense intestinal inflammatory response.
Contributing to the pathogenesis of NEC, milk feeding 
serves as a substrate for bacterial proliferation in the gut. 
Organic acids, short chain fatty acids, carbon dioxide, and 
hydrogen gas are produced by bacterial fermentation milk 
component nutrients. These products of fermentation may 
be toxic to intestinal epithelium and increase intestinal 
distention. In animal studies using an intestinal loop model, 
addition of casein creates a favorable milieu for infiltration 
of cellular elements and vasoactive compounds, leading to 
mucosal injury.17
Human milk is protective
Preterm infants are susceptible to the development of NEC 
because immature immunologic and gastrointestinal sys-
tems result in altered host defense. Factors that contribute 
to innate resistance include luminal pH, enzymes, mucins, 
epithelial barriers, and gut motility, as well as nonspecific 
antimicrobial factors such as lactoferrin and lysozyme. 
Factors present in human milk play a protective role by 
reducing inflammation and the subsequent invasion of 
pathogenic bacterial species in the gastrointestinal tract. 
These factors include the enzyme platelet activating factor 
(PAF) acetylhydrolase, which blunts the immune activation 
sequence promoted by PAF. The local host defenses are 
enhanced by the addition of secretory IgA, lactoferrin, 
lysozyme, and cytokines (IL-10) from human milk. 
Components in human milk, such as epidermal growth fac-
tor, nucleotides, and glutamine also stimulate intestinal 
maturity.18 Human milk antioxidants, such as vitamin E, 
carotene, and glutathione, also reduce oxidative stress.
Human milk oligosaccharides (HMO) are long chain sugars 
that constitute the third most prevalent component in 
human milk. HMOs are prebiotic agents that presumably 
act by enhancing proliferation of beneficial bifidobacterial 
species and preventing the adhesion of pathogenic bacteria 
to the intestinal epithelium. In animal models studied 
under conditions that produce NEC, the HMOs are found to 
prevent intestinal injury compared to synthetic oligosac-
charides. Indeed, human milk diets and formula diets that 
were supplemented with HMOs prevent intestinal injury 
while diets of formula with or without synthetic oligosac-
charides fail to prevent intestinal injury in the model.19 The 
science of HMOs as luminal protective agents is intriguing.
Probiotics reduce NEC in neonates because they improve 
the intestinal barrier function, modulate the immune sys-
tem, suppress the growth or epithelial binding and inva-
sion, of pathogenic bacteria. It is likely that probiotics pro-
vide commensal bacterial colonization similar or additive 
to that promoted by human milk.
Conclusion
These data support recommendations of the American 
Academy of Pediatrics that encourage the use of MOM for 
all very low birth weight infants.2 This recommendation is 
made to preclude the use of intact bovine protein formula 
in the preterm infant population. Given that newer human 
milk fortifiers not containing intact bovine protein are now 
available, the possibility of eliminating NEC with a diet of 
exclusive MOM can be realized.
Funding
This study did not receive funding.
Conflicts of interest
The author declares no conflicts of interest.
References
1. Ahrabi AF, Schanler RJ. Human milk is the only milk for premies 
in the NICU! Early Hum Dev. 2013;89:S51-3.
In time: human milk is the feeding strategy to prevent necrotizing enterecolitis 133
2. Eidelman AI, Schanler RJ. Section on Breastfeeding Executive 
Committee. Breastfeeding and the use of human milk: policy 
statement. Pediatrics. 2012;129:e827-41.
3. Schanler RJ, Shulman RJ, Lau C. Feeding strategies for 
premature infants: beneficial outcomes of feeding fortified 
human milk vs preterm formula. Pediatrics. 1999;103:1150-7.
4. Levy I, Comarsca J, Davidovits M, Klinger G, Sirota L, Linder N. 
Urinary tract infection in preterm infants: the protective role 
of breastfeeding. Pediatr Nephrol. 2009;24:527-31.
5. Lucas A, Cole TJ. Breast milk and neonatal necrotizing 
enterocolitis. Lancet. 1990;336:1519-23.
6. Corpeleijn WE, Kouwenhoven SM, Paap MC, Van Vliet I, 
Scheerder I, Muizer Y, et al. Intake of own mother’s milk during 
the first days of life is associated with decreased morbidity and 
mortality in very low birth weight infants during the first 60 
days of life. Neonatology. 2012;102:276-81.
7. Schanler RJ, Lau C, Hurst NM, Smith EO. Randomized trial of 
donor human milk versus preterm formula as substitutes for 
mothers’ own milk in the feeding of extremely premature 
infants. Pediatrics. 2005;116:400-6.
8. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Higgins RD, 
Langer JC, et al. Persistent beneficial effects of breast milk 
ingested in the neonatal intensive care unit on outcomes of 
extremely low birth weight infants at 30 months of age. 
Pediatrics. 2007;120:e953-9.
9. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O’Shea TM. Early 
human milk feeding is associated with a lower risk of necrotizing 
enterocolitis in very low birth weight infants. J Perinatol. 
2007;27:428-33.
10. Furman L, Taylor G, Minich N, Hack M. The effect of maternal 
milk on neonatal morbidity of very low-birth-weight infants. 
Arch Pediatr Adolesc Med. 2003;157:66-71.
11. Meinzen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, 
Donovan EF. Role of human milk in extremely low birth weight 
infants’ risk of necrotizing enterocolitis or death. J Perinatol. 
2009;29:57-62.
12. Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole 
WK. Growth in the neonatal intensive care unit influences 
neurodevelopmental and growth outcomes of extremely low 
birthweight infants. Pediatrics. 2006;117:1253-61.
13. Hylander MA, Strobino DM, Pezzullo JC, Dhanireddy R. 
Association of human milk feedings with a reduction in 
retinopathy of prematurity among very low birthweight infants. 
J Perinatol. 2001;21:356-62.
14. Okamoto T, Shirai M, Kokubo M, Takahashi S, Kajino M, Takase 
M, et al. Human milk reduces the risk of retinal detachment in 
extremely low-birthweight infants. Pediatr Int. 2007;49:894-7.
15. Kliegman RM, Walker WA, Yolken RH. Necrotizing enterocolitis: 
research agenda for a disease of unknown etiology and 
pathogenesis. Pediatr Res. 1993;34:701-8.
16. Holman RC, Stoll BJ, Clarke MJ, Glass RI. The epidemiology of 
necrotizing enterocolitis infant mortality in the United States. 
Am J Public Health. 1997;87:2026-31.
17. Clark DA, Miller MJ. Intraluminal pathogenesis of necrotizing 
enterocolitis. J Pediatr. 1990;117:S64-7.
18. Dvorak B, Halpern MD, Holubec H, Williams CS, McWilliam DL, 
Dominguez JA, et al. Epidermal growth factor reduces the 
development of necrotizing enterocolitis in a neonatal rat 
model. Am J Physiol Gastrointest Liver Physiol. 2001;282: 
G156-64.
19. Jantscher-Krenn E, Zherebtsov M, Nissan C, Goth K, Guner YS, 
Naidu N, et al. The human milk oligosaccharide disialyllacto-N-
tetraose prevents necrotising enterocolitis in neonatal rats. 
Gut. 2012;61:1417-25.
